Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R Wendel Naumann, Antoine Hollebecque, Tim Meyer, Michael-John Devlin, Ana Oaknin, Joseph Kerger, Jose M López-Picazo, Jean-Pascal Machiels, Jean-Pierre Delord, Thomas R J Evans, Valentina Boni, Emiliano Calvo, Suzanne L Topalian, Tian Chen, Ibrahima Soumaoro, Bin Li, Junchen Gu, Ricardo Zwirtes, Kathleen N Moore, R Wendel Naumann, Antoine Hollebecque, Tim Meyer, Michael-John Devlin, Ana Oaknin, Joseph Kerger, Jose M López-Picazo, Jean-Pascal Machiels, Jean-Pierre Delord, Thomas R J Evans, Valentina Boni, Emiliano Calvo, Suzanne L Topalian, Tian Chen, Ibrahima Soumaoro, Bin Li, Junchen Gu, Ricardo Zwirtes, Kathleen N Moore
Abstract
Purpose: Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report on patients with recurrent/metastatic cervical, vaginal, or vulvar cancers.
Patients and methods: Patients received nivolumab 240 mg every 2 weeks. Although patients with unknown human papillomavirus status were enrolled, patients known to have human papillomavirus-negative tumors were ineligible. The primary end point was objective response rate. Duration of response (DOR), progression-free survival, and overall survival were secondary end points. Safety and patient-reported outcomes were exploratory end points.
Results: Twenty-four patients (cervical, n = 19; vaginal/vulvar, n = 5) were enrolled. Most patients had received prior systemic therapy for metastatic disease (cervical, 78.9%; vaginal/vulvar, 80.0%). Objective response rates were 26.3% (95% CI, 9.1 to 51.2) for cervical cancer and 20.0% (95% CI, 0.5 to 71.6) for vaginal/vulvar cancers. At a median follow-up of 19.2 months, median DOR was not reached (range, 23.3 to 29.5+ months; + indicates a censored observation) in the five responding patients in the cervical cohort; the DOR was 5.0 months in the single responding patient in the vaginal/vulvar cohort. Median overall survival was 21.9 months (95% CI, 15.1 months to not reached) among patients with cervical cancer. Any-grade treatment-related adverse events were reported in 12 of 19 patients (63.2%) in the cervical cohort and all five patients in the vaginal/vulvar cohort; there were no treatment-related deaths. In the cervical cohort, nivolumab treatment generally resulted in stabilization of patient-reported outcomes associated with health status and health-related quality of life.
Conclusion: The efficacy of nivolumab in patients with recurrent/metastatic cervical and vaginal or vulvar cancers is promising and warrants additional investigation. No new safety signals were identified with nivolumab treatment in this population.
Figures
References
- Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19.
- Sinno AK, Saraiya M, Thompson TD, et al. Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet Gynecol. 2014;123:817–821.
- Faber MT, Sand FL, Albieri V, et al. Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer. 2017;141:1161–1169.
- National Cancer Institute: Table 5.1. Cancer of the cervix uteri (invasive). .
- Marth C, Landoni F, Mahner S, et al: Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv72-iv83, 2017 (suppl 4)
- Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Lancet. 2017;390:1654–1663.
- Rosen VM, Guerra I, McCormack M, et al. Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer. 2017;27:1237–1246.
- Long HJ, III, Bundy BN, Grendys EC, Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626–4633.
- Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–4655.
- Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113–3119.
- Boussios S, Seraj E, Zarkavelis G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit Rev Oncol Hematol. 2016;108:164–174.
- National Cancer Institute: Vaginal Cancer Treatment (PDQ)-Health Professional Version. .
- Koh WJ, Greer BE, Abu-Rustum NR, et al. Vulvar Cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:92–120.
- Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27:59–73.
- KEYTRUDA (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co; June 2019.
- OPDIVO (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; May 2019.
- Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;23:541–549.
- Kulangara K, Hanks DA, Waldroup S, et al: Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx. J Clin Oncol 35:e14589-e14589, 2017 (15; suppl)
- Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–413.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
- Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29–41.
- Greenwood M: The errors of sampling of the survivorship tables. Reports on Public Health and Statistical Subjects, no. 33. London, United Kingdom, HMSO, 1926.
- Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the Phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470–1478.
- Frenel JS, Le Tourneau C, O’Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: Results from the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017;35:4035–4041.
- Santin A, Deng W, Frumovitz MM, et al: A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. J Clin Oncol 36, 2018 (suppl; abstr 5536)
- Burd EM. Human papillomavirus laboratory testing: The changing paradigm. Clin Microbiol Rev. 2016;29:291–319.
Source: PubMed